<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040144</url>
  </required_header>
  <id_info>
    <org_study_id>ACH443-005</org_study_id>
    <nct_id>NCT00040144</nct_id>
  </id_info>
  <brief_title>Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV)&#xD;
      activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic&#xD;
      hepatitis B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the safety and antiviral activity of 3 dose levels of ACH126, 433 over a&#xD;
      12-week treatment in the population is described.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety concerns&#xD;
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>85</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH126, 433</intervention_name>
    <other_name>b-L-Fd4C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Chronic HBV infection, known to be hepatitis B surface antigen (HbsAg) positive ≥ 6&#xD;
             months&#xD;
&#xD;
          -  On lamivudine, either 100 or 150 milligrams daily for the treatment of chronic&#xD;
             hepatitis B infection and exhibit a 2-3 log decrease in HBV deoxyribonucleic acid&#xD;
             (DNA) levels followed by a rebound of at least 1.5 log HBV DNA or&#xD;
&#xD;
               -  Achieved an HBV DNA level of &lt; 10,000 copies/milliliter (mL) HBV DNA on at least&#xD;
                  2 occasions and have rebounded to &gt; 100,000 copies/mL HBV DNA, or&#xD;
&#xD;
               -  Have a demonstrable lamivudine -resistant genotype regardless of treatment&#xD;
                  history.&#xD;
&#xD;
          -  Hepatitis B e-antigen positive.&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) negative.&#xD;
&#xD;
          -  Serum alanine aminotransferase ≥ 1.5 and ≤ 10x times the upper limit of normal (ULN).&#xD;
&#xD;
          -  Hemoglobin ≥ 10 grams/deciliter or hematocrit ≥ 30% (in the absence of blood&#xD;
             transfusions or erythropoietin treatment in the preceding 2 weeks).&#xD;
&#xD;
          -  Platelet count &gt;75,000/cubic millimeters (in the absence of ongoing granulocyte&#xD;
             colony-stimulating factor therapy).&#xD;
&#xD;
          -  Serum creatinine &lt; 1.1x the ULN.&#xD;
&#xD;
          -  Negative radiologic screening test (ultrasound, computerized tomography scan, or&#xD;
             magnetic resonance imaging) for hepatocellular carcinoma within 6 months prior to&#xD;
             entry.&#xD;
&#xD;
          -  Prothrombin time/international normalize ratio &lt; 2.&#xD;
&#xD;
          -  Participants of reproductive capability must utilize an approved form of birth&#xD;
             control.&#xD;
&#xD;
          -  All women of child-bearing capability must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity of 24 international units/liter of beta human chorionic&#xD;
             gonadotropin) within 72 hours prior to the start of study medication.&#xD;
&#xD;
          -  Participants must be able to provide written informed consent.&#xD;
&#xD;
          -  Participant must be available for follow-up for a period of 20 weeks.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Hepatitis C co-infection.&#xD;
&#xD;
          -  Alcohol abuse.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Inability to tolerate oral medication.&#xD;
&#xD;
          -  Any clinical condition or prior therapy that, in the Investigator's opinion, would&#xD;
             make the participant unsuitable for the study or unable to comply with the dosing&#xD;
             requirements.&#xD;
&#xD;
          -  Use of any investigational drug.&#xD;
&#xD;
          -  Participants with decompensated liver disease.&#xD;
&#xD;
          -  Use of any concomitant herbal treatments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 21, 2002</study_first_submitted>
  <study_first_submitted_qc>June 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2002</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E-Antigen Positive</keyword>
  <keyword>Lamivudine-resistant Chronic Hepatitis B</keyword>
  <keyword>Achillion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexelvucitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

